Uncategorized

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents

Pharma doesn’t just “own” patents—it engineers time.
In a world where blockbuster revenues are increasingly squeezed by generic competition, the real battleground is often not the original patent grant. It’s the calendar. The ability to extend exclusiv…

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents Read Post »

Uncategorized

Pick the Right FDA Pathway and You Own the Market. Pick the Wrong One and You’re Funding Your Competitor.

Pick the Right FDA Pathway—and You Own the Market. Pick the Wrong One—and You’re Funding Your Competitor.
In pharma, the fastest way to lose a market isn’t a failed clinical trial. It’s a strategic misstep that happens long before launch—often at the l…

Pick the Right FDA Pathway and You Own the Market. Pick the Wrong One and You’re Funding Your Competitor. Read Post »

Biotechblog
Scroll to Top